Fda advisory committee votes unanimously in favor of comirnaty® booster for emergency use in people 65 and older and certain high-risk populations

New york and mainz, germany, september 17, 2021—pfizer inc. (nyse: pfe) and biontech se (nasdaq: bntx) announced today that the u.s. food and drug administration's (fda) vaccines and related biological products advisory committee (vrbpac) voted unanimously to recommend the fda grant emergency use authorization (eua) for a booster dose of comirnaty® (covid-19 vaccine, mrna) in individuals 65 years of age and older and individuals at high risk of severe covid-19. the committee recommended that the additional dose be administered at least six months after the two-dose series. the panel also agreed that healthcare workers and others at high risk for occupational exposure should be included in this eua.
BNTX Ratings Summary
BNTX Quant Ranking